ClinicalTrials.gg

Program

Arsenic Trioxide

Also written as “arsenic trioxide”, “IV Arsenic Trioxide” and “Treatment A: Arsenic Trioxide (ATO) Intravenous”.

Its studies are mostly in Leukemia, Promyelocytic, Acute · Multiple Myeloma · Bronchiolitis Obliterans Syndrome · Leukemia · Leukemia, Myeloid, Acute, led by 6 companies.

Furthest: phase 3, since Jun 6, 20019 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Swedish Orphan Biovitrum30 open or runningphase 2since Jun 6, 2001Jun 6, 2001none ahead
SDK Therapeutics21 open or runningphase 3since Dec 16, 2025Jan 23, 2025Jun 2027phase 3 · NCT07296445
Medsenic10 open or runningphase 2since Oct 28, 2016Oct 28, 2016none ahead
Oncotherapeutics10 open or runningphase 2since Jun 10, 2004Jun 10, 2004none ahead
Syros Pharmaceuticals10 open or runningphase 1since Aug 3, 2021Aug 3, 2021none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Aug 6, 2007Aug 6, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2001First studies: 2 phase 2 studies in Multiple MyelomaNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT00017433, NCT00017069
  2. Jul 11, 2001Phase 2 study in LeukemiaSwedish Orphan Biovitrum · NCT00020969 · United States
  3. Jun 10, 2004Oncotherapeutics's first study: phase 2 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT00085345 · United States
  4. Aug 6, 2007Teva Pharmaceutical Industries's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00513305 · 67 enrolled · United States, Canada
  5. Oct 28, 2016Medsenic's first study: phase 2 study in Bronchiolitis Obliterans SyndromeNew to MedsenicMedsenic · NCT02966301 · 21 enrolled
  6. Aug 3, 2021Syros Pharmaceuticals's first study: phase 1 study in Leukemia, Promyelocytic, AcuteNew to Syros PharmaceuticalsSyros Pharmaceuticals · NCT04996030 · 16 enrolled · United States
  7. Jan 23, 2025SDK Therapeutics's first study: phase 1 study in Leukemia, Promyelocytic, AcuteNew to SDK TherapeuticsSDK Therapeutics · NCT06882031 · 12 enrolled · Hong Kong
  8. Dec 16, 2025Phase 3 study in Leukemia, Promyelocytic, AcutePhase 3 reachedSDK Therapeutics · NCT07296445 · 120 planned

Ahead

  1. Jun 2027Primary completion: phase 3 study in Leukemia, Promyelocytic, AcuteSDK Therapeutics · NCT07296445

TargetBeta

TXNRD1 →read by rule
“Thioredoxin reductase 1 inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07296445Leukemia, Promyelocytic, Acute3Not yet recruitingSDK TherapeuticsJun 2027120
NCT06882031Leukemia, Promyelocytic, Acute · Hong Kong1CompletedSDK TherapeuticsJun 25, 202512
NCT04996030Leukemia, Promyelocytic, Acute · United States1SuspendedSyros PharmaceuticalsJan 3, 202416
NCT02966301Bronchiolitis Obliterans Syndrome2CompletedMedsenicJun 202021
NCT00513305Leukemia, Myeloid, Acute · United States, Canada3TerminatedTeva Pharmaceutical IndustriesJul 200967
NCT00085345Multiple Myeloma · United States2WithdrawnOncotherapeutics0
NCT00020969Leukemia · United States2TerminatedSwedish Orphan BiovitrumJan 2005
NCT00017433Multiple Myeloma · United States2TerminatedSwedish Orphan BiovitrumJan 2005
NCT00017069Multiple Myeloma · United States2TerminatedSwedish Orphan BiovitrumJan 2005

How it is read

Names in the registry

  • “arsenic trioxide”, 4 entries
  • “IV Arsenic Trioxide”, 1 entry
  • “Treatment A: Arsenic Trioxide (ATO) Intravenous”, 1 entry
  • “Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state”, 1 entry
  • “Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.